Llama’s carry a specific type of antibody that offer a series of opportunities. It is small, easy to engineer, low in immunogenicity and has further advantages over commonly known first generation animal and human antibodies.
In the last decade the interest to use next generation llama antibodies, called VHHs, as diagnostic or therapeutic is rapidly increasing. Several VHHs are in clinical evaluation and products are being lined up for approval.
The VHH opportunity goes beyond the human pharmaceutical market, amongst others the VHH cost price allows application in the canine and equine markets.
Partners
